Aytu BioScience Inc Stock News

Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call.

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of $3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to host conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / May 14, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharma...

DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025, after the market close on Wednesday, May 14, 2025. The Company has scheduled a conference call and webcast that same day, Wednesda...

Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30 p.m. Pa...

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At ...

Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / F...

DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on Wednesday, February 12, 2025. The Company has scheduled a conference call and webcast that same da...

DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The fireside chat will ta...